Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1998;10:1-40.
Davis SF, Byers RJ, Lindegren ML.
et al. Prevalence and incidence of vertically acquired HIV infection in the
United States. JAMA.1995;274:952-955.
Byers RH, Caldwell MB, Davis S.
et al. Projection of AIDS and HIV incidence among children born infected with
HIV. Stat Med.1998;17:169-181.
Connor EM, Sperling RS, Gelber R.
et al. Reduction of maternal-infant transmission of human immunodeficiency
virus type 1 with zidovudine treatment. N Engl J Med.1994;331:1173-1180.
Sperling RS, Shapiro DE, Coombs RW.
et al. Maternal viral load, zidovudine treatment, and the risk of transmission
of human immunodeficiency virus type 1 from mother to infant. N Engl J Med.1996;335:1621-1629.
Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use
of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep.1994;43(RR-11):1-20.
Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency
virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep.1995;44(RR-7):1-15.
Fiscus SA, Adimora AA, Schoenback VJ.
et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission
in rural and urban counties. JAMA.1996;275:1483-1488.
Boyer PJ, Dillon M, Navaie M.
et al. Factors predictive of maternal-fetal transmission of HIV-1: preliminary
analysis of zidovudine given during pregnancy and/or delivery. JAMA.1994;271:1925-1930.
Simonds RJ, Steketee R, Nesheim S.
et al. Impact of zidovudine use on risk and risk factors for perinatal transmission
of HIV: Perinatal AIDS Collaborative Transmission Studies. AIDS.1998;12:301-308.
Cooper ER, Nugent RP, Diaz C.
et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use
during pregnancy, and the subsequent reduction in vertical transmission of
human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis.1996;174:1207-1211.
Stiehm ER, Lambert JS, Mofenson LM.
et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune
immunoglobulin for reducing perinatal HIV transmission from HIV-infected women
with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol
185. J Infect Dis.1999;179:567-575.
Shaffer N, Chuachoowong R, Mock PA.
et al. Short course zidovudine for perinatal HIV 1 transmission in Bangkok,
Thailand: a randomised controlled trial. Lancet.1999;353:773-780.
Wiktor SZ, Ekpini E, Karon JM.
et al. Short course oral zidovudine for prevention of mother-to-child transmission
of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet.1999;353:781-785.
Centers for Disease Control and Prevention. Update: perinatally acquired HIV/AIDS—United States, 1997. MMWR Morb Mortal Wkly Rep.1997;46:1086-1092.
Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodeficiency
syndrome. MMWR Morb Mortal Wkly Rep.1987;36(suppl 1):S1-S15.
Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus
infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep.1994;43(RR-12):1-10.
Green T. Using surveillance data to monitor trends in the AIDS epidemic. Stat Med.1998;17:143-154.
Karon JM, Devine OJ, Morgan WM. Predicting AIDS incidence by extrapolating from recent trends. In: Castillo-Chavez C, ed. Mathematical and Statistical
Approaches to AIDS Epidemiology: Lecture Notes in Biomathematics. Vol
83. Berlin, Germany: Springer-Verlag; 1989:58-88.
Wang M-C. The analysis of retrospectively ascertained data in the presence of
reporting delays. J Am Stat Assoc.1992;87:397-406.
Barnhart HX, Caldwell MB, Thomas P.
et al. Natural history of human immunodeficiency virus disease in perinatally
infected children: an analysis from the Pediatric Spectrum of Disease project. Pediatrics.1996;97:710-716.
Auger I, Thomas P, de Gruttola V.
et al. Incubation periods for paediatric AIDS patients. Nature.1988;336:575-577.
Byers RH, Oxtoby M, Caldwell MB. Survival of children with HIV infection: evidence for two distinct
populations [abstract]. Paper presented at: IX International AIDS Conference; June 6-11,
1993; Berlin, Germany.
Blanche S, Newell ML, Mayaux MJ.
et al. Morbidity and mortality in European children vertically infected by
HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol.1997;14:442-450.
Davis SF, Rosen DH, Steinberg S.
et al. Trends in HIV prevalence among US childbearing women, United States,
1989-1994. J Acquir Immune Defic Syndr Hum Retrovirol.1998;19:158-164.
Buehler JW, Berkelman RL, Stehr-Green JK. The completeness of AIDS surveillance. J Acquir Immune Defic Syndr.1992;5:257-264.
Rosenblum L, Buehler JW, Morgan MW.
et al. The completeness of AIDS case reporting, 1988: a multisite collaborative
project. Am J Public Health.1992;82:1495-1499.
Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral
drugs in pregnant women infected with HIV-1 for maternal health and for reducing
perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep.1998;47(RR-2):1-30.
Culnane M, Fowler MG, Lee SS.
et al. Lack of long-term effects of in utero exposure to zidovudine among
uninfected children born to HIV-infected women. JAMA.1999;281:151-157.
Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol.1997;176:478-489.
Simpson BJ, Shapiro ED, Andiman WA. Reduction in the risk of vertical transmission of HIV-1 associated
with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol.1997;14:145-152.
Lansky A, Jones JL, Wan PT.
et al. Trends in zidovudine prescription for pregnant women infected with
HIV. J Acquir Immune Defic Syndr Hum Retrovirol.1998;18:289-292.
The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human
immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med.1999;340:977-987.
The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of
vertical HIV-1 transmission: a randomised clinical trial. Lancet.1999;353:1035-1039.
Centers for Disease Control and Prevention. Recommendations for assisting in the prevention of perinatal transmission
of human T-lymphotropic virus type III/lymphadenopathy-associated virus and
acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep.1985;34:721-726, 731-732.
Karon J, Rosenberg PS, McQuillan G.
et al. Prevalence of HIV infection in the United States, 1985-1992. JAMA.1996;276:126-131.
Wortley P, Fleming P. AIDS in women in the United States: recent trends. JAMA.1997;298:911-916.
Centers for Disease Control and Prevention. 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally
exposed to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep.1995;44(RR-4):1-11.
Simonds RJ, Lindegren ML, Thomas P.
et al. Prophylaxis against Pneumocystis carinii pneumonia
among children with perinatally acquired HIV infection in the United States. N Engl J Med.1995;332:786-790.
Working Group on Antiretroviral Therapy, National Pediatric HIV Resource
Center. Antiretroviral therapy and medical management of the human immunodeficiency
virus-infected child. Pediatr Infect Dis J.1993;12:513-522.
Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. MMWR Morb Mortal Wkly Rep.1998;47(RR-5):39-82.
Englund JA, Baker CJ, Raskino C.
et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic
HIV-infected children. N Engl J Med.1997;336:1704-1712.
Luzuriaga K, Bryson Y, Krogstad P.
et al. Combination treatment with zidovudine, didanosine, and nevirapine in
infants with human immunodeficiency virus type 1 infection. N Engl J Med.1997;336:1343-1349.
Mueller BU, Zuckerman J, Nelson RP.
et al. Update on the pediatric phase I/II study of the protease inhibitor
ritonavir (ABT-538) [abstract]. Paper presented at: Fourth Conference on Retroviruses and Opportunistic
Infections; January 24, 1997; Washington, DC.
Krogstad P, Wiznia A, Luziarg K.
et al. Evidence of potent antiviral activity in a phase I/II study of nelfinavir
mesylate (Viracept) in HIV-infected children [abstract]. Paper presented at: Fifth Conference on Retroviruses and Opportunistic
Infections; February 3, 1998; Chicago, Ill.
Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep.1998;47:43.
Centers for Disease Control and Prevention. Update: trends in AIDS incidence—United States, 1996. MMWR Morb Mortal Wkly Rep.1997;46:861-867.
American Academy of Pediatrics, Committee on Pediatric AIDS. Surveillance of pediatric HIV infection. Pediatrics.1998;101:315-318.
Institute of Medicine, National Research Council. Reducing the odds: Preventing Perinatal Transmission
of HIV in the United States. Washington, DC: National Academy Press; 1999.
Centers for Disease Control and Prevention. Success in implementing PHS guidelines to reduce perinatal transmission
of HIV—1993, 1995, and 1996. MMWR Morb Mortal Wkly Rep.1998;47:688-691.